
Novo Nordisk’s biopharma arm saw sales grow to DKK 4.7bn (USD 713.9m) in the fourth quarter of 2021, up from DKK 4.4bn (USD 668.35m) the same period last year, according to Novo’s financial figures, which were released on Wednesday.
According to estimates collected by the company itself prior to the report, analysts had predicted that Novo’s biopharma sales would amount to DKK 4.8bn (USD 729.1m).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app